awmsg logo



paclitaxel albumin-bound nanoparticles (Abraxane®)


Reference No. 1999

Publication date:
19/09/2014


Appraisal information

paclitaxel albumin-bound nanoparticles (Abraxane®) 5 mg/ml powder for suspension for infusion


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 23/07/2014
AWMSG meeting date: 03/09/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 2414
Ministerial ratification: 19/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (ID1058) NICE GUIDANCE ISSUED AUGUST 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download